Search Type: drug or dietary supplement name
Search Term: losartan (COZAAR)


Drug Profiles | Worst Pills, Best Pills Newsletter Articles | Additional Information from Public Citizen

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include drug profiles where your selected drug is a secondary subject of discussion

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion
  • Spironolactone: Review of a ‘Water Pill’ [hide all summaries]
    (March 2017)
    Spironolactone is a diuretic (water pill) that has been used for decades to treat certain patients with high blood pressure, heart failure, swelling (water retention) and other conditions. Find out who is most likely to benefit from using this drug and who should avoid it because of its dangerous adverse effects.
  • Risks but No Benefits to Taking Newest Drugs For Type 2 Diabetes [hide all summaries]
    (August 2015)
    The airwaves are filled with ads promoting the newest class of diabetes medications, often referred to as “flozins.” In this article, we review the serious safety concerns that have prompted us to designate all flozins as Do Not Use.
  • Dangers of Taking Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Together [hide all summaries]
    (September 2011)
    Find out how using a combination of two drugs, one from each of these two families, can increase the risks of kidney toxicity and dangerously higher blood levels of potassium compared to use of one of these two families of drugs alone. The article lists 10 different drugs in the first class and seven in the second class. Worse yet, most of the patients in the study were prescribed the combination to treat conditions for which the combination has not proven to be beneficial.
  • Drug Mix-Ups [hide all summaries]
    (June 2011)
    This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.
  • Nonsteroidal Anti-Inflammatory Drugs Can Make Blood Pressure Hard to Control [hide all summaries]
    (February 2009)
    Twenty different NSAIDS (nonsteroidal antiinflammatory drugs) are listed in this article that can adversely affect your blood pressure control. The article discusses the way in which this happens and what you can do about it.
  • Potassium Increases Due to Drug Interactions Can Be Dangerous [hide all summaries]
    (November 2008)
    One of the most common drug interactions occurs when patients take two or more drugs that can each increase blood potassium levels. The resulting condition, hyperkalemia (increased blood potassium levels), can cause nausea, fatigue, muscle weakness or tingling sensations, as well as heart abnormalities, showing up as an abnormal electrocardiogram. In some cases it can be fatal. The article lists 50 drugs which, especially when used in combination, can cause hyperkalemia.
  • BIDIL, a Heart Drug Targeted at African Americans, Stirs Complex Controversy [hide all summaries]
    (September 2005)
    You should only be using BiDil for congestive heart failure in combination with other drugs for this condition. For one-fourth of the cost, with the cooperation of your physician, you can get prescriptions for the two generically-available drugs that comprise BiDil, isosorbide dinitrate and hydralazine.
  • DO NOT USE UNTIL 2011 Eplerenone (INSPRA) For High Blood Pressure [hide all summaries]
    (December 2003)
    This statement appears in the professional product labeling, or package insert, for eplerenone: “The principal risk of INSPRA is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal, arrhythmias (heart rhythm disturbances).”
  • Merck’s Promotion Of Its Arthritis Drug Rofecoxib (VIOXX) Crosses Legal Lines And Poses Public Danger [hide all summaries]
    (November 2001)
    The Food and Drug Administration (FDA) on September 17, 2001 made public a Warning Letter it had issued to Merck & Co. about a false and misleading promotional campaign that the pharmaceutical giant had been conducting on behalf of its blockbuster arthritis drug rofecoxib (VIOXX).The FDA said, "Specifically, your promotional campaign discounts the fact that in the VIGOR study, patients on Vioxx were observed to have a four to five fold increase in myocardial infarctions (MIs) compared to patients on the comparator nonsteroidal anti-inflammatory drug (NSAID), Naprosyn (naproxen)."

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion

SHOW primary search results for losartan (COZAAR)

Copyright © 2017 Public Citizen's Health Research Group. All rights reserved. https://www.worstpills.org/